ZHANG Jia-tao, ZHONG Wen-zhao. Neoadjuvant Alectinib for ALK+ Stage Ⅱ~Ⅲ Non-Small Cell Lung Cancer: Analysis of NAUTIKA1 Study[J]. Journal of Evidence-Based Medicine, 2023, 23(1): 26-29. DOI: 10.12019/j.issn.1671-5144.2023.01.005
|
Citation:
|
ZHANG Jia-tao, ZHONG Wen-zhao. Neoadjuvant Alectinib for ALK+ Stage Ⅱ~Ⅲ Non-Small Cell Lung Cancer: Analysis of NAUTIKA1 Study[J]. Journal of Evidence-Based Medicine, 2023, 23(1): 26-29. DOI: 10.12019/j.issn.1671-5144.2023.01.005
|
ZHANG Jia-tao, ZHONG Wen-zhao. Neoadjuvant Alectinib for ALK+ Stage Ⅱ~Ⅲ Non-Small Cell Lung Cancer: Analysis of NAUTIKA1 Study[J]. Journal of Evidence-Based Medicine, 2023, 23(1): 26-29. DOI: 10.12019/j.issn.1671-5144.2023.01.005
|
Citation:
|
ZHANG Jia-tao, ZHONG Wen-zhao. Neoadjuvant Alectinib for ALK+ Stage Ⅱ~Ⅲ Non-Small Cell Lung Cancer: Analysis of NAUTIKA1 Study[J]. Journal of Evidence-Based Medicine, 2023, 23(1): 26-29. DOI: 10.12019/j.issn.1671-5144.2023.01.005
|
DownLoad: